Marizyme Stock Revenue
| MRZM Stock | USD 0.05 0.01 25.00% |
Marizyme fundamentals help investors to digest information that contributes to Marizyme's financial success or failures. It also enables traders to predict the movement of Marizyme OTC Stock. The fundamental analysis module provides a way to measure Marizyme's intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Marizyme otc stock.
Marizyme |
Marizyme OTC Stock Revenue Analysis
Marizyme's Revenue is income that a firm generates from business activities such us rendering services or selling goods to customers. It is a crucial part of a business and an essential item when evaluating a company's financial statements. Revenues from a firm's primary business operations can be reported on the income statement as sales revenue, net sales, or simply sales, depending on the industry in which a given company operates.
Current Marizyme Revenue | 210.28 K |
Most of Marizyme's fundamental indicators, such as Revenue, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Marizyme is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Revenue is typically recorded when cash or cash equivalents are exchanged for services or goods and can include products or services discounts, promotions, as well as early payments on invoices or services rendered in advance.
| Competition |
Based on the latest financial disclosure, Marizyme reported 210.28 K of revenue. This is 100.0% lower than that of the Software sector and 99.97% lower than that of the Information Technology industry. The revenue for all United States stocks is 100.0% higher than that of the company.
Marizyme Revenue Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Marizyme's direct or indirect competition against its Revenue to detect undervalued stocks with similar characteristics or determine the otc stocks which would be a good addition to a portfolio. Peer analysis of Marizyme could also be used in its relative valuation, which is a method of valuing Marizyme by comparing valuation metrics of similar companies.Marizyme is currently under evaluation in revenue category among its peers.
Marizyme Fundamentals
| Return On Equity | -0.5 | |||
| Return On Asset | -0.15 | |||
| Operating Margin | (180.85) % | |||
| Current Valuation | 17.35 M | |||
| Shares Outstanding | 10.13 M | |||
| Shares Owned By Insiders | 2.04 % | |||
| Price To Book | 0.37 X | |||
| Price To Sales | 133.06 X | |||
| Revenue | 210.28 K | |||
| Gross Profit | 129.93 K | |||
| EBITDA | (10.83 M) | |||
| Net Income | (11 M) | |||
| Cash And Equivalents | 2.04 M | |||
| Cash Per Share | 0.05 X | |||
| Total Debt | 495.32 K | |||
| Debt To Equity | 0.07 % | |||
| Current Ratio | 1.74 X | |||
| Book Value Per Share | 1.00 X | |||
| Cash Flow From Operations | (5.79 M) | |||
| Earnings Per Share | (0.39) X | |||
| Number Of Employees | 11 | |||
| Beta | 0.36 | |||
| Market Capitalization | 5.07 M | |||
| Total Asset | 66 M | |||
| Z Score | 6.0 | |||
| Net Asset | 66 M |
About Marizyme Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Marizyme's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Marizyme using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Marizyme based on its fundamental data. In general, a quantitative approach, as applied to this otc stock, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Building efficient market-beating portfolios requires time, education, and a lot of computing power!
The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.
Try AI Portfolio ArchitectOther Information on Investing in Marizyme OTC Stock
Marizyme financial ratios help investors to determine whether Marizyme OTC Stock is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in Marizyme with respect to the benefits of owning Marizyme security.